Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04861051 · ClinicalTrials.gov registry record · Phase 1
Understanding Ketamine's Dissociative Effects (KD Study)
A Phase 1 study of Epilepsy, sponsored by Stanford University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT04861051: Recruiting Phase 1 study of Epilepsy, sponsored by Stanford University.
NCT04861051 is a Phase 1 study of Epilepsy that is actively recruiting participants, run by Stanford University. The registered enrollment target is 20 participants, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04861051, a Phase 1 study of Epilepsy, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to understand how ketamine brings about dissociative symptoms.
Primary Outcome
The CADSS is an instrument for the measurement of dissociative symptoms. The CADSS comprises 23 subjective items and participant's responses are coded on a 5-point scale (0 = Not at all; 4 = Extreme). The higher the number on the CADSS, the more severe the symptoms.
Conditions Studied
Interventions
- DRUG Ketamine
Study Locations (1)
California
- Stanford University School of Medicine - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-07-26 |
| Est. Completion | 2028-08-01 |
| Phase | Phase 1 |
What NCT04861051 shows while recruiting
NCT04861051 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Epilepsy appearing as the primary indexed condition, and to 1 intervention - of which Ketamine is the first listed.
NCT04861051 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04861051 about?
NCT04861051 is a clinical study titled "Understanding Ketamine's Dissociative Effects (KD Study)". The purpose of this study is to understand how ketamine brings about dissociative symptoms.
What is the current status of trial NCT04861051?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2021-07-26. Estimated completion is 2028-08-01.
What conditions does trial NCT04861051 study?
This clinical trial studies the following conditions: Epilepsy.
What interventions are being tested in trial NCT04861051?
The interventions under investigation include: Ketamine (DRUG).
Who is sponsoring clinical trial NCT04861051?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04861051 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04861051's enrollment target sits among peer trials
20 131st of 160 higher than 24 of 160 other Epilepsy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Epilepsy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042
RECRUITING · Phase 1
-
A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy
RECRUITING · Phase 1
-
A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy
RECRUITING · Phase 1
-
Microelectrode Recordings From the Vagus Nerve in Awake Humans
RECRUITING · Phase 1
-
Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy
RECRUITING · Phase 1
-
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SIF001 in Healthy Subjects and in Epilepsy Patients
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI